NSCLC HER3 AE Management

CME

Optimizing HER3-Targeted Therapy for NSCLC: Strategies for Early Detection and Management of Adverse Events 

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 05, 2024

Expiration: June 04, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this module, Karen Reckamp, MD, MS, discusses current data on how to identify and manage adverse events (AEs) associated with HER3-targeted therapies for the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC). Mechanisms of resistance to ADCs are also highlighted including emerging approaches to overcome resistance and optimize patient care. For more information on understanding the biological rationale for targeting HER3 in NSCLC and a summary of the current clinical trial data on HER3-targeted therapies in NSCLC, please click here.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions. 

How many people with NSCLC do you provide care for in a typical week? 

You are seeing a patient in a clinical trial with patritumab deruxtecan (HER3-DXd) for EGFR-mutated NSCLC. Routine bloodwork shows that the patient’s neutrophil level is 1500 neutrophils/mm3. All other blood test results are normal. 
What would you do to address this patient’s neutropenia?